Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer.
Samaranayake, Govindi J; Troccoli, Clara I; Huynh, Mai; Lyles, Rolando D Z; Kage, Karen; Win, Andrew; Lakshmanan, Vishalakshi; Kwon, Deukwoo; Ban, Yuguang; Chen, Steven Xi; Zarco, Enrique Rodriguez; Jorda, Merce; Burnstein, Kerry L; Rai, Priyamvada.
; 8(1): 1204, 2017 10 31.
Artigo em Inglês | MEDLINE | ID: mdl-29089489
Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.
Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications.
Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
Differential expression of AP-1 transcription factors in human prostate LNCaP and PC-3 cells: role of Fra-1 in transition to CRPC status.
Integrative clinical genomics of advanced prostate cancer.
Third-line treatment and <sup>177</sup>Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.
Clinical phenotypes of castration-resistant prostate cancer.
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.
Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration.
Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies.